Fingerprint
Dive into the research topics where Joleen M Hubbard is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 1 Active
-
A phase II, multicenter, single-arm study of pemigatinib in patients with metastatic or unresectable colorectal cancer harboring FGFR alterations
Wheless, M. C., Zemla, T. J., Hubbard, J. M., Strickler, J. H., Gbolahan, O. B., Wilson, L., Waechter, B., Ou, F. S., Nixon, A. B., Bekaii-Saab, T. S. & Ciombor, K. K., Jun 1 2025, In: Oncologist. 30, 6, oyaf069.Research output: Contribution to journal › Article › peer-review
Open Access -
Comparison of survival outcomes for patients with Lynch vs non-Lynch syndrome and microsatellite unstable colorectal cancer treated with immunotherapy
Eslinger, C., Walden, D., McGary, A., Emiloju, O., Ahn, D., Sonbol, M. B., Bekaii-Saab, T., Zhu, M., Hubbard, J. & Wu, C., Feb 15 2025, In: Cancer. 131, 4, e35756.Research output: Contribution to journal › Article › peer-review
-
Fruquintinib in less pretreated patients: Multivariate profile-matching analysis of FRESCO-2 to FRESCO
Dasari, A., Eng, C., Lonardi, S., Garcia-Carbonero, R., Masuishi, T., Cremolini, C., Ghiringhelli, F., Hubbard, J., Bekaii-Saab, T., Jones, J., Xu, R. H., Shen, L., Xu, J., Bai, Y., Deng, Y., Yuan, Y., Wei, W., Lin, J., Chen, L. & Yang, Z. & 3 others, , Sep 9 2025, In: European Journal of Cancer. 227, 115641.Research output: Contribution to journal › Article › peer-review
Open Access -
Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer
Yeku, O. O., Barve, M., Tan, W. W., Wang, J., Patnaik, A., LoRusso, P., Richardson, D. L., Naqash, A. R., Lynam, S. K., Fu, S., Gordon, M., Hubbard, J., Kummar, S., Kyriakopoulos, C., Dowlati, A., Chamberlain, M. & Winer, I., Mar 13 2025, In: Journal for ImmunoTherapy of Cancer. 13, 3, e010959.Research output: Contribution to journal › Article › peer-review
Open Access -
Onvansertib in Combination with Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial
Ahn, D. H., Ridinger, M., Cannon, T. L., Mendelsohn, L., Starr, J. S., Hubbard, J. M., Kasi, A., Barzi, A., Samuëlsz, E., Karki, A., Subramanian, R. A., Yemane, D., Kim, R., Wu, C. C., Croucher, P. J. P., Smeal, T., Kabbinavar, F. F. & Lenz, H. J., Mar 1 2025, In: Journal of Clinical Oncology. 43, 7, p. 840-851 12 p.Research output: Contribution to journal › Article › peer-review
Open Access